CURE Stock Overview
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Biocure Technology Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.015 |
| 52 Week High | CA$0.10 |
| 52 Week Low | CA$0.01 |
| Beta | 2.42 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 50.00% |
| 3 Year Change | -88.46% |
| 5 Year Change | -96.67% |
| Change since IPO | -96.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| CURE | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | -5.8% | -0.6% |
| 1Y | 50.0% | -37.3% | 3.9% |
Return vs Industry: CURE exceeded the Canadian Biotechs industry which returned 19% over the past year.
Return vs Market: CURE exceeded the Canadian Market which returned 2.7% over the past year.
Price Volatility
| CURE volatility | |
|---|---|
| CURE Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 13.6% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: CURE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CURE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Simon Cheng | www.biocuretech.com |
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products.
Biocure Technology Inc. Fundamentals Summary
| CURE fundamental statistics | |
|---|---|
| Market cap | CA$1.41m |
| Earnings (TTM) | CA$2.46m |
| Revenue (TTM) | n/a |
0.6x
P/E Ratio0.0x
P/S RatioIs CURE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CURE income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | -CA$2.46m |
| Earnings | CA$2.46m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.026 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.3% |
How did CURE perform over the long term?
See historical performance and comparison